- Home
- PSNL vs LXEO Comparison
PSNL vs LXEO Comparison
Compare PSNL & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PSNL | LXEO |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 746.8M | 731.3M |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | PSNL | LXEO |
|---|---|---|
| Price | $9.99 | $7.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $11.00 | ★ $18.60 |
| AVG Volume (30 Days) | 1.4M | ★ 1.8M |
| Earning Date | 02-26-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,103,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.83 | $1.45 |
| 52 Week High | $11.40 | $10.99 |
Technical Indicators
Market Signals| Indicator | PSNL | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 61.58 | 35.65 |
| Support Level | $7.87 | $6.90 |
| Resistance Level | $9.74 | $10.75 |
| Average True Range (ATR) | 0.64 | 0.85 |
| MACD | 0.18 | -0.32 |
| Stochastic Oscillator | 79.35 | 12.73 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.